Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Boroleum is a classic over-the-counter (OTC) topical nasal ointment that has been used since 1906 to soothe and protect dry, sore, and irritated nasal passages, as well as chapped lips and minor skin irritations. Originally developed by Sinclair Pharmacal and currently manufactured and distributed by Reliable-1 Laboratories, Boroleum is formulated with active ingredients including camphor (1%), menthol (0.54%), and white petrolatum (97.92%), along with inactive ingredients eucalyptol and methyl salicylate. It functions as an external analgesic and skin protectant. Menthol and camphor act on transient receptor potential (TRP) channels (such as TRPM8, TRPV1, TRPV3, and TRPA1) to produce a cooling, soothing, and mild anesthetic sensation that relieves pain and itching. White petrolatum serves as an occlusive barrier that prevents transepidermal water loss, helping to moisturize and protect the skin barrier from harsh, dry, or cold climates.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Boroleum.